Home > Insider Trading > Filing (0000947871-21-000712)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1551986	9 Meters Biopharma Inc.	NMTR	Pharmaceutical Preparations (2834)	273948465

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569590	Ltd. Gp Israel Orbimed	601 Lexington Avenue, 54Th Floor New York NY 10022-4629		No	No	Yes	No
1569821	Partnership Limited Gp Biofund Israel Orbimed	601 Lexington Avenue, 54Th Floor New York NY 1022-4629		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-06-23	841,650	$1.36	24,875,105	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-06-24	319,255	$1.38	24,555,850	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-06-25	15,989,876	$1.21	8,565,974	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	31,944	Indirect	See Footnotes

Footnotes

These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund.
These shares of the Issuer's common stock are held of record by Nissim Darvish ("Darvish"). Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.